Furthermore, in a novel assay that quantified non-HLA-restricted anti-TAA CTL priming, addition of HDACIs to HSVGM-CSF treatment of melanoma cells enhanced both the magnitude and range of TAAs expressed by tumor cells as targets for CD8 T cell recognition (Figure 5). This evidence concerns the gene CSF2 and melanoma.